DGAP-News: Eckert & Ziegler takes over Brazilian isotope specialists - stronger presence in South America


 
DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Acquisition Eckert & Ziegler takes over Brazilian isotope specialists - stronger presence in South America 03.09.2014 / 09:43 --------------------------------------------------------------------- Berlin, September, 3, 2014. Eckert & Ziegler Strahlen- und Medizintechnik AG acquired the Isotope business unit of REM Indústria e Comércio Ltda. (REM), based in Sao Paulo, Brazil, effective September 1, 2014 via its subsidiary Eckert & Ziegler Isotope Products Holdings GmbH. The approximately 30 employees have been integrated into TOF Comercial Ltda. (TOF), Sao Paulo, which Eckert & Ziegler has also acquired and has been renamed as Eckert & Ziegler Brasil Comercial Ltda. and does business as Eckert & Ziegler Brasil Isotope Solutions. TOF specializes in importing isotope technology to Brazil and is one of the leading providers of nuclear medical components in South America. The company has been selling Eckert & Ziegler products for decades. It has nationwide sales structures and all the required local authorizations to handle substances based on isotope technology. "Eckert & Ziegler is focusing on organic growth as well as strategic acquisitions in the expansion of its business. This acquisition fits well into our growth strategy in South America, one of the world's most dynamic healthcare markets. The expanded sales structures also result in promising market opportunities for the Radiopharma and Radiation Therapy segments," said Frank Yeager, Head of the Isotope Products segment of Eckert & Ziegler AG. About Eckert & Ziegler With almost 700 employees, Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700) is one of the world's largest providers of components based on isotope technology for radiation therapy and nuclear medicine. Contributing to saving lives. If you have any questions, please contact: Eckert & Ziegler AG Karolin Riehle, Investor Relations Robert-Rössle-Str. 10, 13125 Berlin, Germany Tel.: +49 (0) 30 / 94 10 84-138 [email protected] www.ezag.de --------------------------------------------------------------------- 03.09.2014 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: Eckert & Ziegler Strahlen- und Medizintechnik AG Robert-Rössle-Str.10 13125 Berlin Germany Phone: 49 30 941084-138 Fax: 49 30 941084-112 E-mail: [email protected] Internet: www.ezag.de ISIN: DE0005659700 WKN: 565970 Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart; Freiverkehr in Berlin, Düsseldorf, Hamburg, München End of News DGAP News-Service --------------------------------------------------------------------- 285310 03.09.2014


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 138,63 168,71 178,49 176,14 180,44 222,26 246,09
EBITDA1,2 26,62 32,14 43,13 44,64 57,04 55,52 58,83
EBITDA-Marge3 19,20 19,05 24,16 25,34 31,61 24,98
EBIT1,4 17,97 23,39 32,06 33,69 47,45 44,54 45,45
EBIT-Marge5 12,96 13,86 17,96 19,13 26,30 20,04 18,47
Jahresüberschuss1 15,12 16,89 22,48 23,11 34,66 29,75 26,77
Netto-Marge6 10,91 10,01 12,59 13,12 19,21 13,39 10,88
Cashflow1,7 26,83 21,21 40,43 36,79 33,86 34,30 47,40
Ergebnis je Aktie8 0,70 0,78 1,07 1,11 1,66 1,41 1,26
Dividende8 0,20 0,30 0,42 0,45 0,50 0,50 0,17
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2022 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Mazars

INVESTOR-INFORMATIONEN
©boersengefluester.de
Eckert & Ziegler
WKN Kurs in € Einschätzung Börsenwert in Mio. €
565970 35,180 Halten 744,83
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
21,99 26,15 0,82 38,70
KBV KCV KUV EV/EBITDA
3,37 15,71 3,03 12,14
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,50 0,05 0,14 28.05.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
14.05.2024 09.08.2024 14.11.2024 22.03.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-13,42% -5,26% -14,82% -18,60%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Eckert & Ziegler Strahlen- und Medizintechnik AG  ISIN: DE0005659700 können Sie bei EQS abrufen


Medtech , 565970 , EUZ , XETR:EUZ